KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Equity Ratio (2016 - 2025)

Pacific Biosciences Of California has reported Equity Ratio over the past 16 years, most recently at 0.01 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.01 for Q4 2025, down 98.3% from a year ago — trailing twelve months through Dec 2025 was 0.01 (down 98.3% YoY), and the annual figure for FY2025 was 0.01, down 98.3%.
  • Equity Ratio for Q4 2025 was 0.01 at Pacific Biosciences Of California, down from 0.04 in the prior quarter.
  • Over the last five years, Equity Ratio for PACB hit a ceiling of 0.4 in Q3 2023 and a floor of 0.01 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.34 (2022), compared with a mean of 0.28.
  • Biggest five-year swings in Equity Ratio: soared 75.33% in 2022 and later plummeted 98.3% in 2025.
  • Pacific Biosciences Of California's Equity Ratio stood at 0.39 in 2021, then decreased by 19.17% to 0.32 in 2022, then increased by 26.09% to 0.4 in 2023, then rose by 0.06% to 0.4 in 2024, then plummeted by 98.3% to 0.01 in 2025.
  • The last three reported values for Equity Ratio were 0.01 (Q4 2025), 0.04 (Q3 2025), and 0.07 (Q2 2025) per Business Quant data.